Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report
about
Brainstem Glioma in AdultsDIPG in Children - What Can We Learn from the Past?Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationMolecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and TreatmentRadiotherapy and "new" drugs-new side effects?Adult brainstem gliomasClinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma.Advances in the management of paediatric high-grade glioma.Imaging of central nervous system tumors in children: advances and limitations.Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.An operational perspective of challenging statistical dogma while establishing a modern, secure distributed data management and imaging transport system: the Pediatric Brain Tumor Consortium phase I experience.Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).Three-dimensional susceptibility-weighted imaging and two-dimensional T2*-weighted gradient-echo imaging of intratumoral hemorrhages in pediatric diffuse intrinsic pontine glioma.Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstemChildhood brain tumors: epidemiology, current management and future directions.Adaptive dose-finding studies: a review of model-guided phase I clinical trials.Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas.Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas.Management of diffuse pontine gliomas in children: recent developments.Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsPhase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.Brainstem glioma: a review.A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group.Management of high-grade gliomas in the pediatric patient: Past, present, and future.Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine gliomaGenome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.Genomic aberrations in pediatric diffuse intrinsic pontine gliomasNVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study.Diffuse intrinsic pontine glioma: poised for progress.Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.Neurotoxicity of biologically targeted agents in pediatric cancer trialsTargeted therapy for BRAFV600E malignant astrocytoma.Biologically targeted therapeutics in pediatric brain tumors.Pediatric CNS tumors: current treatment and future directions.Diagnostic and therapeutic stratification of childhood brain tumors: implications for translational research.Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathwayPhase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
P2860
Q26739232-A6206AB1-85F4-47FF-A837-5C8DCE8BD5AFQ26777843-52D6C977-7B02-4DFE-9063-C53E7F5A3F4DQ26781833-E50E1770-6387-486F-9B17-11734C7C330FQ26785952-26872439-CCE2-4812-B114-2FB9F65E80CDQ26861498-1E0D5D88-80DC-4F64-99AA-3F65B1AA7B24Q30457821-E569ADD7-55F9-4084-BB50-3F29D7EC790DQ30652433-822014E3-A636-4A35-B6B7-FA1EE9FE71FCQ30870633-932B309E-D4EC-420C-BB38-3EEBCB2A383FQ33379510-5138048B-B0C9-48E9-A624-9F0E3276AF76Q33395853-6D215C2A-0B8E-4112-9E7A-0D0905CE1B06Q33571622-D1568ED5-8BA9-41B1-93DF-77C06AA638A5Q33574578-99B202E0-AFFE-442E-80A8-32C9C88376ADQ33705503-761DFCF9-0D2C-433F-B6DD-994F37062C1DQ33796170-8D4FF818-F87C-4237-B492-932134A2EDD7Q33970971-30813CA6-B7B1-4CFD-8C4F-4E86418C4264Q34001009-910B23A7-FFAC-4BC0-B6AB-6FE5861AE982Q34184430-6369EF3D-2798-4674-BE3C-530E4A1BE4D3Q34191508-D7FD66C2-3319-4D8E-A1F1-5806DDEEE42AQ34347540-0BF801FA-100C-4C82-8BA3-C5A63D2D810FQ34480582-B92F081C-BBCB-429F-9DF2-3818A9997B6AQ34488803-E7325772-0352-422C-BE52-50CD2F7ABF6AQ34628180-F1C91768-E42E-49D7-BBB7-A9D4DEB120B8Q34722457-9B5DCD3D-9F9D-4587-812E-70014EDDE9A7Q34722864-F1F7E4C5-7182-4695-B5A9-436538831F8DQ35206259-3296F596-2288-414C-BC15-A48F50C54DB1Q35230772-107F6D99-D86A-4C5F-AB4D-DAAB6BD08D27Q35532490-B8A38F73-7B3E-4DB2-881B-D2F8BD96244FQ35760625-B67AED9F-FEF0-4CC0-A9B0-6DC342776FB3Q35849961-E1038385-3A0D-4A45-B2A4-2831ABDE6EC7Q36485991-5040F2B8-F452-41EE-8FCA-50604FFC4727Q36492719-2480A404-F115-428E-9E38-0E5E0FC07963Q36694926-65271545-3FF3-44CF-9F3F-610F52F7F0EAQ36766221-B9B56789-2881-47C3-B8EC-4AC5F5493143Q36800148-59D8338D-A34C-49AA-B31D-68D1944766A4Q36844744-8A1B7C81-CFCE-4642-9800-0C977ACB11D5Q36902043-B3F95B29-B19C-4D5C-8C3D-534E5A731C5EQ36908083-0FDDEB35-6762-4828-990A-08A2BB0F418FQ36936139-22033E31-5EFA-4D99-8CEC-B3B910375C36Q37027010-12E1EE2C-A5FF-4BF2-B739-E52A5B3238ACQ37121681-21DF5338-8143-41D4-8002-3C7A676D209E
P2860
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Phase I trial of imatinib in c ...... Brain Tumor Consortium report
@ast
Phase I trial of imatinib in c ...... Brain Tumor Consortium report
@en
type
label
Phase I trial of imatinib in c ...... Brain Tumor Consortium report
@ast
Phase I trial of imatinib in c ...... Brain Tumor Consortium report
@en
prefLabel
Phase I trial of imatinib in c ...... Brain Tumor Consortium report
@ast
Phase I trial of imatinib in c ...... Brain Tumor Consortium report
@en
P2093
P2860
P50
P1433
P1476
Phase I trial of imatinib in c ...... Brain Tumor Consortium report
@en
P2093
Anthony Murgo
Anu Banerjee
Ian F Pollack
J Russell Geyer
James M Boyett
Larry E Kun
Matthew J Krasin
Michael Hayes
Michael L Hancock
Peter Phillips
P2860
P304
P356
10.1215/15228517-2006-031
P577
2007-02-09T00:00:00Z